Gyre Therapeutics Inc

GYRE is in Stage 2 advancing with a down long-term trend but has formed an emerging HH/HL sequence and a momentum breakout, signaling medium-term bullish asymmetry. However, price is extended above the rising 9EMA and 21EMA and facing the declining 200 DMA, suggesting entries should be deferred. Preferred execution zones are pullbacks into the rising short-term EMAs or near the recent breakout support area. The long-term downtrend under the 200-day SMA remains intact, posing structural risk until cleared and held.

• ↑China liver-fibrosis trial shows promising efficacy signals in under-served market.
• ↑Full-year revenue guidance reaffirmed despite wider Q2 loss, highlighting management confidence.
• ↓Q2 revenue missed expectations and loss per share widened sequentially.